Kyverna Therapeutics (KYTX) Income from Continuing Operations (2023 - 2026)
Kyverna Therapeutics' (KYTX) quarterly Income from Continuing Operations came in at 74163000.0 in Q1 2026, down 62.83% YoY from 199529091.97 in Q1 2025, and down 96.55% on a QoQ basis from 37732000.0 in Q4 2025.
Powered by 
Analysis
Kyverna Therapeutics (KYTX) Income from Continuing Operations (2023 - 2026) Analysis & Trends
Kyverna Therapeutics (KYTX) has 4 years of Income from Continuing Operations data on file, last reported at 74163000.0 in Q1 2026.
- Quarterly Income from Continuing Operations fell 62.83% year-over-year to 74163000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 208952000.0 (down 22.46% YoY) and the FY2025 annual result came in at 204554000.0, down 56.97% from the prior year.
- Income from Continuing Operations eased to 74163000.0 in Q1 2026, from 37732000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 11661000.0 in Q1 2023 to a low of 74163000.0 in Q1 2026.
- A 4-year average of 36149384.62 and a median of 40424000.0 in 2024 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2024 — Income from Continuing Operations plunged 203.32% — and 2025, when it gained 6.66%.
- Tracing KYTX's Income from Continuing Operations over 4 years: stood at 20635000.0 in 2023, then tumbled by 95.9% to 40424000.0 in 2024, then grew by 6.66% to 37732000.0 in 2025, then sank by 96.55% to 74163000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 74163000.0 (Q1 2026), 37732000.0 (Q4 2025), and 52850000.0 (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 601.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Kyverna Therapeutics | 505.44 Mn | 505.44 Mn | - | -38.30 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -38.30 Mn |
| Mar 31, 2026 | -39.71 Mn |
| Dec 31, 2025 | -37.82 Mn |
| Sep 30, 2025 | -36.73 Mn |
| Jun 30, 2025 | -42.06 Mn |
| Mar 31, 2025 | -44.61 Mn |
| Dec 31, 2024 | -37.49 Mn |
| Sep 30, 2024 | -34.45 Mn |
| Jun 30, 2024 | -28.78 Mn |
| Mar 31, 2024 | -26.67 Mn |
| Dec 31, 2023 | -20.64 Mn |
| Sep 30, 2023 | -15.45 Mn |
| Jun 30, 2023 | -13.08 Mn |
| Mar 31, 2023 | -11.14 Mn |